These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 16534099)

  • 1. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.
    Tilley BC; Palesch YY; Kieburtz K; Ravina B; Huang P; Elm JJ; Shannon K; Wooten GF; Tanner CM; Goetz GC;
    Neurology; 2006 Mar; 66(5):628-33. PubMed ID: 16534099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
    Shoulson I
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S160-6. PubMed ID: 9749589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.
    NINDS NET-PD Investigators
    Neurology; 2006 Mar; 66(5):664-71. PubMed ID: 16481597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design.
    Rascol O
    Neurology; 2009 Feb; 72(7 Suppl):S51-8. PubMed ID: 19221315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A responsive outcome for Parkinson's disease neuroprotection futility studies.
    Elm JJ; Goetz CG; Ravina B; Shannon K; Wooten GF; Tanner CM; Palesch YY; Huang P; Guimaraes P; Kamp C; Tilley BC; Kieburtz K;
    Ann Neurol; 2005 Feb; 57(2):197-203. PubMed ID: 15668964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II trials with a prospective control.
    Jung SH
    Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applying a phase II futility study design to therapeutic stroke trials.
    Palesch YY; Tilley BC; Sackett DL; Johnston KC; Woolson R
    Stroke; 2005 Nov; 36(11):2410-4. PubMed ID: 16224086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group.
    Ann Neurol; 1996 Jan; 39(1):29-36. PubMed ID: 8572663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis.
    Gordon PH
    Muscle Nerve; 2009 Jun; 39(6):858-60. PubMed ID: 19382169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
    Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening potential therapies: lessons learned from new paradigms used in Parkinson disease.
    Tilley BC; Galpern WR
    Stroke; 2007 Feb; 38(2 Suppl):800-3. PubMed ID: 17261742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can we eliminate placebo in ALS clinical Trials?
    Simmons Z
    Muscle Nerve; 2009 Jun; 39(6):861-5. PubMed ID: 19382170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II clinical trials in oncology: strengths and limitations of two-stage designs.
    Schlesselman JJ; Reis IM
    Cancer Invest; 2006; 24(4):404-12. PubMed ID: 16777694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining heterogeneity in phase II trial designs may improve success in phase III.
    Tuma RS
    J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788
    [No Abstract]   [Full Text] [Related]  

  • 20. Sequential designs for phase III clinical trials incorporating treatment selection.
    Stallard N; Todd S
    Stat Med; 2003 Mar; 22(5):689-703. PubMed ID: 12587100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.